e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Treatment of IPF
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON)
Bruno Crestani (Paris, France), Bruno Crestani, Takashi Ogura, Katy Pelling, Carl Coeck, Manuel Quaresma, Michael Kreuter, Mitchell Kaye
Source:
International Congress 2015 – Treatment of IPF
Session:
Treatment of IPF
Session type:
Oral Presentation
Number:
4495
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Bruno Crestani (Paris, France), Bruno Crestani, Takashi Ogura, Katy Pelling, Carl Coeck, Manuel Quaresma, Michael Kreuter, Mitchell Kaye. Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON). Eur Respir J 2015; 46: Suppl. 59, 4495
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment I
Year: 2016
Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim results
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
A Phase 2, double-blind, placebo-controlled study of N–acetylcysteine in combination with pirfenidone in patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 6
Year: 2014
Pirfenidone post-authorization safety registry (PASSPORT) update
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON
Source: International Congress 2016 – IPF treatment II
Year: 2016
Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015
Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP)
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Bosentan does not improve outcome in patients with steroid-resistant pulmonary sarcoidosis – Results from a double-blind placebo-controlled phase 2 trial
Source: International Congress 2014 – Sarcoidosis
Year: 2014
Idiopathic pulmonary fibrosis (IPF): observations from a Phase 2 trial of GLPG1205 (PINTA)
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020
Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials
Source: International Congress 2016 – IPF treatment I
Year: 2016
Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
LATE-BREAKING ABSTRACT: Simtuzumab in idiopathic pulmonary fibrosis: Results of a randomized clinical trial
Source: International Congress 2016 – IPF treatment I
Year: 2016
Inhaled rhGM-CSF (molgramostim) in the first randomised, double-blind, placebo-controlled, international trial in patients with autoimmune alveolar proteinosis (aPAP)
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Pirfenidone post-authorization safety registry (PASSPORT) – Interim analysis of IPF treatment
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Exploratory analysis of phase III trial of pirfenidone: Most effective population in patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis
Year: 2010
Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study
Source: Eur Respir Rev 2008; 17: 116-122
Year: 2008
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Effect of baseline statin use on benefit of nintedanib
Source: International Congress 2016 – IPF treatment II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept